Jiangsu Hengrui Medicine has patented a method for treating cancer using a combination of an anti-PD-1 antibody and apatinib. The drug is administered orally at a dose ranging from 125 mg to 375 mg. GlobalData’s report on Jiangsu Hengrui Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Jiangsu Hengrui Medicine Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jiangsu Hengrui Medicine, Cancer treatment biomarkers was a key innovation area identified from patents. Jiangsu Hengrui Medicine's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Combination of anti-pd-1 antibody and vegfr inhibitor for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Jiangsu Hengrui Medicine Co Ltd

A recently granted patent (Publication Number: US11866500B2) discloses a method for treating cancer in patients by administering an anti-PD-1 antibody and apatinib or its pharmaceutically acceptable salt. The anti-PD-1 antibody specified in the patent includes specific amino acid sequences for both the light and heavy chain variable regions. The method involves oral administration of apatinib at doses ranging from 125 mg to 375 mg, targeting various types of cancer such as breast, lung, liver, gastric, intestinal, renal, melanoma, and non-small cell lung cancer. Patients who have previously undergone chemotherapy without success are also considered eligible for this treatment regimen.

Furthermore, the patent outlines specific dosages and administration frequencies for both the anti-PD-1 antibody and apatinib, emphasizing the importance of precise dosing for optimal therapeutic outcomes. The anti-PD-1 antibody can be administered at doses ranging from 2 mg/kg to 6 mg/kg of body weight or from 100 mg to 1000 mg per administration, with recommended doses falling between 200 mg to 600 mg per administration. Apatinib or its salt is suggested to be taken orally at doses of 125 mg, 250 mg, or 375 mg once daily, in conjunction with the anti-PD-1 antibody. The patent provides detailed guidance on the administration of these compounds, aiming to enhance the efficacy of cancer treatment while minimizing potential side effects.

To know more about GlobalData’s detailed insights on Jiangsu Hengrui Medicine, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies